で公開中です！詳しく見る

Bolt Biotherapeutics

BOLT

時価総額 $771万

4.00 USD

-0.24

5.66%

終値時点更新済み 10月16日 16:00 EDT

1日

-5.66%

5日間

-3.15%

1か月

10.19%

3か月

-4.53%

6か月

-16.84%

年初来

-30.92%

1年

-31.74%

5年間

-98.4%

10年間

-99.38%

概要： Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

従業員数： 23

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 50%

ネガティブ 50%

ネガティブ

Zacks Investment Research

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.57 per share versus the Zacks Consensus Estimate of a loss of $2.97. This compares to a loss of $4.46 per share a year ago.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

ニュートラル

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results Cash balance of $18.1 million as of June 30, 2026 anticipated to fund operations into 1Q 2027 REDWOOD CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2026, and provided a business update.

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

ニュートラル

Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project

VANCOUVER, BC / ACCESS Newswire / June 12, 2026 / Bolt Metals Corp. ("Bolt" or the "Company") (CSE:BOLT)(OTCQB:PCRCF)(FSE:A3D8AK), is pleased to announce that, further to its press releases dated May 13, 2026, the letter of intent dated October 23, 2025, and the definitive option agreement dated May 12, 2026, as amended (the "Option Agreement"), with Max Iron Brazil Ltd. ("MaxIron"), an entity controlled by Max Resource Corp. ("Max"), pursuant to which Bolt has the right to acquire 100% of the Florália High Purity Iron Property (title no.

Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project

ネガティブ

Zacks Investment Research

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.31 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $5.8 per share a year ago.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Lags Revenue Estimates

ニュートラル

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

ネガティブ

Zacks Investment Research

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q4 Loss, Tops Revenue Estimates

ニュートラル

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full-year ended December 31, 2025, and provided a business update.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

ニュートラル

Bolt Biotherapeutics to Participate in Upcoming March Conferences

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:

Bolt Biotherapeutics to Participate in Upcoming March Conferences

ニュートラル

Zacks Investment Research

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.72 per share versus the Zacks Consensus Estimate of a loss of $5.07. This compares to a loss of $8 per share a year ago.

Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates

ニュートラル

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Initial clinical data for BDC-4182 Phase 1 dose escalation study expected in 3Q 2026 Cash balance of $38.8 million as of September 30, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the third quarter ended September 30, 2025, and provided a business update.

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています